GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shionogi & Co Ltd (STU:SH0) » Definitions » Cyclically Adjusted Revenue per Share

Shionogi (STU:SH0) Cyclically Adjusted Revenue per Share : €2.62 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Shionogi Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shionogi's adjusted revenue per share for the three months ended in Mar. 2025 was €0.763. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.62 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Shionogi's average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shionogi was 8.30% per year. The lowest was 2.40% per year. And the median was 3.70% per year.

As of today (2025-05-21), Shionogi's current stock price is €14.00. Shionogi's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €2.62. Shionogi's Cyclically Adjusted PS Ratio of today is 5.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shionogi was 8.40. The lowest was 4.61. And the median was 6.28.


Shionogi Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Shionogi's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shionogi Cyclically Adjusted Revenue per Share Chart

Shionogi Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 2.48 2.50 2.38 2.62

Shionogi Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 2.30 2.55 2.53 2.62

Competitive Comparison of Shionogi's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shionogi's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shionogi's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shionogi's Cyclically Adjusted PS Ratio falls into.


;
;

Shionogi Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shionogi's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.763/111.1000*111.1000
=0.763

Current CPI (Mar. 2025) = 111.1000.

Shionogi Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.464 98.400 0.524
201509 0.556 98.500 0.627
201512 0.667 98.100 0.755
201603 0.674 97.900 0.765
201606 0.623 98.100 0.706
201609 0.723 98.000 0.820
201612 0.847 98.400 0.956
201703 0.702 98.100 0.795
201706 0.620 98.500 0.699
201709 0.757 98.800 0.851
201712 0.703 99.400 0.786
201803 0.649 99.200 0.727
201806 0.719 99.200 0.805
201809 0.638 99.900 0.710
201812 0.810 99.700 0.903
201903 0.874 99.700 0.974
201906 0.707 99.800 0.787
201909 0.748 100.100 0.830
201912 0.812 100.500 0.898
202003 0.723 100.300 0.801
202006 0.646 99.900 0.718
202009 0.665 99.900 0.740
202012 0.650 99.300 0.727
202103 0.618 99.900 0.687
202106 0.575 99.500 0.642
202109 0.649 100.100 0.720
202112 0.641 100.100 0.711
202203 0.978 101.100 1.075
202206 0.561 101.800 0.612
202209 0.617 103.100 0.665
202212 1.480 104.100 1.580
202303 0.699 104.400 0.744
202306 0.808 105.200 0.853
202309 0.875 106.200 0.915
202312 0.782 106.800 0.813
202403 0.693 107.200 0.718
202406 0.675 108.200 0.693
202409 0.862 108.900 0.879
202412 0.873 110.700 0.876
202503 0.763 111.100 0.763

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Shionogi  (STU:SH0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shionogi's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.00/2.62
=5.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shionogi was 8.40. The lowest was 4.61. And the median was 6.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shionogi Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Shionogi's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shionogi Business Description

Industry
Traded in Other Exchanges
Address
1-8, Doshomachi 3-chome, Chuo-ku, Osaka, JPN, 541-0045
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi Headlines

No Headlines